NSC 286193
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
SummaryA phase I trial of 2-β-D-ribofuranosylthiazole-4-carboxamide (NCS 286193, tiazofurin) was conducted using a 5-day i.v…
SummaryTiazofurin (2-β-D-ribofuranosylthiazole-4-carboxamide, TCAR) is a synthetic C-nucleoside that demonstrated significant in…
The authors studied the metastasis-inhibiting effect of various dosages of tiazofurin in mice inoculated with a low (LLT) and a…
Tiazofurin (2-beta-D-ribofuranosyl-4-thiazole-carboxamide; NSC 286193), an antitumor carbon-linked nucleoside that inhibits IMP…
A patient with refractory acute myeloid leukemia was treated with tiazofurin, an agent that causes inhibition of tumor cell…
Tiazofurin (2-beta-D-ribofuranosylthiazole-4-carboxamide, TCAR, Riboxamide, NSC 286193) is a novel C-nucleoside with antitumor…
A Phase I trial of 2-beta-D-ribofuranosylthiazole-4-carboxamide (NSC 286193, tiazofurin) was conducted using a 5-day continuous…
Tiazofurin (2-beta-D-ribofuranosylthiazole-4-carboxamide), a new nucleoside antimetabolite, was evaluated in a phase I trial…